Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression profiles of PBMC in CRPC patients receiving persornalized peptide vaccination

ABSTRACT: Personalized peptide vaccination (PPV) is one of the attractive immunotherapy with high immune-boosting effects. However, as with most therapeutic agents, PPV does not elicit beneficial immune and/or clinical responses in all of the treated cancer patients. To identify prognostic biomarker for the selection of patients most likely to benefit from PPV, we conducted whole genome gene expression analysis of prevaccination peripheral blood mononuclear cells (PBMCs) of 112 castration-resistant prostate cancer (CRPC) patients.

ORGANISM(S): Homo sapiens

PROVIDER: GSE53922 | GEO | 2015/02/01

SECONDARY ACCESSION(S): PRJNA233966

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

CRPC biomarker via proteomic analysis

Project description:Identifying biological change from hormone-naive prostate cancer to CRPC is a major clinical challenge for developing therapeutic agents. Although the pathways that lead to CRPC are not fully understood, recent evidence demonstrates that androgen signaling is often maintained through varied mechanisms. Here, we investigated PCa tissues at each stage of progression from benign prostatic hyperplasia (BPH) to CRPC based on quantitative proteomic technology, including tissues after ADT therapy. MS-based quantitative proteomics approach based on 6-plex TMT (126-131) was performed in patient tissues from T2G2 to CRPC, and benign prostatic hyperplasia (BPH) patient tissues were used as a control. We analyzed the peptide samples using two types of high resolution and accuracy mass spectrometers as LTQ orbitrap velos and Q-exactive mass spectrometer. In total, 4,768 proteins were identified in this study, among which 4,069 proteins were quantified in the combined prostate cancer tissues. Among the quantified proteins, DEPs were 865 (21.2%), those with a quantitative ratio greater than 2 were considered as upregulated, whereas those with a quantitative ratio of less than 0.5 as downregulated. Based on quantitative protein results, we performed systematic bioinformatics analysis including GO, Interpro, KEGG pathway, functional enrichment-based cluster analysis on DEPs. Finally, we found that 15 proteins including FOXA1 and HMGN1-3 between T3G3, T3GX, and CRPC were increased despite ADT treatment. Among all target, we verified increased level of FOXA1 and HMGN1-3 in CRPC by immunoblotting and indirect ELISA. In summary, we provides intracellular mechanical changes on PCa tissues according to treatment before and after ADT by mean of regulating ADT treatment. In addition, this results were identified through bioinformatics analysis, and those were suggested as potential CRPC-related factors.

2021-09-10 | PXD023592 | Pride

3D genome in CRPC

Project description:3D genome in CRPC

| PRJEB29051 | ENA

HSPC and CRPC

Project description:Genetic alteration between HSPC and CRPC

| PRJEB32473 | ENA

Chimæra CRPC

Project description:Exome sequencing of 10 biopsies from the same CRPC tumor

| PRJEB19193 | ENA

MeRIP sequencing for CSPC vs CRPC samples

Project description:To investigate if there is a difference of N6-methyladenosine(m6A) modification between castration-resistant prostate cancer (CRPC) and castration-sensitive prostate cancer (CSPC), we collected 30 specimens, including 15 CRPC and 15 CSPC, to perform RNA-seq and MeRIP-seq. All specimens were postoperative tissues and each 5 CRPC or CSPC specimens were mixed into 1 sample to meet the RNA dosage of RNA-seq and MeRIP-seq.

2023-01-03 | GSE221961 | GEO

Castration-Resistant Prostate Cancer (CRPC)

Project description:Gene expression data from Agilent-014850 4x44K human expression array for CRPC Prostate Cancer study with Xenograph data.

2011-12-31 | GSE33277 | GEO

CRPC cfDNA exon 8 AR sequencing

Project description:Sequencing of the exon 8 of AR from cfDNA isolated from blood of CRPC patients

| PRJEB12109 | ENA

LSD1 inhibition disrupts super-enhancer activities in CRPC [scRNA-seq]

Project description:Our studies revealed a novel oncogenic function of LSD1 in driving PCa progression by activating MYC signaling and mediating CRPC SEs activities, cotargeting LSD1 and BRD4 achieved significant synergistic effects in repressing CRPC tumor growth

2023-06-01 | GSE209888 | GEO

LSD1 inhibition disrupts super-enhancer activities in CRPC [RNA-seq]

2023-06-01 | GSE209887 | GEO

LSD1 inhibition disrupts super-enhancer activities in CRPC [ChIP-seq]

2023-06-01 | GSE209886 | GEO